—
The appointment of Dr Roberts significantly strengthens the Lentitek team both commercially and scientifically. Founded in 2019 by Dr Adam Inche, Lentitek had developed a technology which addresses key issues within the manufacturing of advanced cell and gene therapies. These advanced therapies provide curative treatments for previously intractable cancers and other genetic conditions but are difficult and expensive to manufacture and deliver. Since incorporation Lentitek has moved rapidly to develop and commercialise its unique technology attracting significant interest from major players in the field.
Adam Inche, Chief Executive Officer of Lentitek commented: “It is with enormous pleasure that we welcome Dr Roberts to the Lentitek team. Michael brings a phenomenal depth of knowledge and experience both scientifically and commercially which will prove invaluable as we scale the business.
“Lentitek’s unique technology and application to advanced cell and gene therapy markets has close parallels to those which Dr Roberts commercialised so successfully at Synpromics. By leveraging his experience our team hopes to rapidly build on our strong initial successes in the market place.”
As a prominent scientist in the field of gene regulation, Dr Michael Roberts founded Synpromics in 2010, which pioneered the industrialisation of synthetic promoter design. After achieving significant commercial success in the cell and gene therapy space, Synpromics was acquired by Asklepios Biopharmaceuticals Inc (AskBio) in 2019.
On his appointment as Director at Lentitek, Dr Roberts commented: “I have been keenly interested in Lentitek and was delighted to be asked to join the team. Their technology provides an elegant solution to some of the most pressing concerns in lentivirus manufacturing.” Roberts currently serves as CEO for Chromatin Bioscience Ltd, a leading provider of synthetic promoter design services for the cell and gene therapy sector with a prestigious list clients.
Lentitek also recently secured a highly competitive Innovate UK grant for a £400,000 project to further develop its technology for cutting edge in-vivo CAR-T applications where the patients’ own immune cells are modified within the body rather than in a lab.
Lentitek Co-Founder Leif Anderson said: “Winning such a competitive grant is a tremendous endorsement of the technology and team Lentitek has built since incorporating. With Michael to guide us I believe the business is poised to make a real difference to the market and to patient outcomes."
More information can be found at the UKRI page.
About Us: About Lentitek Lentitek Ltd is an Edinburgh based biotechnology company that is developing manufacturing technologies for lentiviral vectors used in advanced therapies such as adoptive cell therapies and gene therapies. Established in 2019 by Dr Adam Inche, Lentitek was awarded a Scottish Enterprise Smart grant in 2021 to demonstrate a proof of concept of the manufacturing technology. The company received significant recognition in 2022 at the Scottish Edge awards, winning the top prize of £100,000. After receiving a £250,000 investment in 2023, Lentitek is focused on demonstrating its technology with clinical applications, focusing on the key commercial market of CAR-T cell therapy. For more information on Lentitek, please visit www.lentitek.com follow on LinkedIn www.linkedin.com/company/lentitek or contact info@lentitek.com About Dr Michael Roberts Dr Michael Roberts is currently the CEO of Chromatin Bioscience Ltd, a company that he founded in 2022. Dr Roberts was awarded his PhD in Biochemistry at the University of Cambridge and subsequently completed post-doctoral positions at RHUL in London, and NHRF in Greece. He then spent five years running Gene Therapy R&D activities for Regulon Inc, spending three years on the board. In 2010 he established Synpromics Ltd, the first company to successfully use functional genomics data to design and commercialize synthetic promoters for enhanced gene control in the Biotech sector. In the following 10 years, Synpromics grew into the leading supplier of novel synthetic promoters and gene control elements to both the gene therapy and bioprocessing industries, until it was acquired by Asklepios Biopharmaceuticals Inc in 2019. Asklepios was subsequently acquired by Bayer in 2020. Dr Roberts is a member of the Board of Trustees at Medical Research Scotland and a Fellow of the Royal Society of Biology.
Contact Info:
Name: Adam Inche
Email: Send Email
Organization: Lentitek
Website: http://www.lentitek.com/
Release ID: 89142012
Google
RSS